Advertisement
Screener

Lunai Bioworks Inc. (LNAI) Comprehensive Income

2.8 / 5 stars · 68/120 Roast Me

Lunai Bioworks Inc. Comprehensive Income

Lunai Bioworks Inc. (LNAI) reported Comprehensive Income of -$2.59 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-15.

Financial Statements › Income Statement

us-gaap:ComprehensiveIncomeNetOfTax · last filed 2026-05-15

  • Lunai Bioworks Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-03-31 was -$2.59M, a 153.78% decline year-over-year.
  • Lunai Bioworks Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-12-31 was -$1.81M.
  • Lunai Bioworks Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-09-30 was -$8.12M.
  • Lunai Bioworks Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-06-30 was -$116.69M.
  • Lunai Bioworks Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2025 was -$167.02M.
  • Lunai Bioworks Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was -$88.57M.
  • Lunai Bioworks Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was -$39.68M.
  • Lunai Bioworks Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2022 was -$113.45M.
Period endComprehensive Income (Loss), Net of Tax, Attributable to Parent 3 monthComprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month as first filedComprehensive Income (Loss), Net of Tax, Attributable to Parent 6 monthComprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month as first filedComprehensive Income (Loss), Net of Tax, Attributable to Parent 9 monthComprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month as first filedComprehensive Income (Loss), Net of Tax, Attributable to Parent 12 monthComprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month as first filed
2026-03-31-$2.59M
10-Q · filed 2026-05-15
-$4.40M
derived: sum of 2 quarters · filed 2026-05-15
-$12.52M
10-Q · filed 2026-05-15
-$129.22M
derived: sum of 4 quarters · filed 2026-05-15
2025-12-31-$1.81M
10-Q · filed 2026-02-17
-$9.93M
10-Q · filed 2026-02-17
-$126.63M
derived: sum of 3 quarters · filed 2026-02-17
-$121.81M
derived: sum of 4 quarters · filed 2026-05-15
2025-09-30-$8.12M
10-Q · filed 2025-11-14
-$124.82M
derived: sum of 2 quarters · filed 2025-11-14
-$120.00M
derived: sum of 3 quarters · filed 2026-05-15
-$137.40M
derived: sum of 4 quarters · filed 2026-05-15
2025-06-30-$116.69M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-09-29
-$111.88M
derived: sum of 2 quarters · filed 2026-05-15
-$129.28M
derived: sum of 3 quarters · filed 2026-05-15
-$167.02M
10-K · filed 2025-09-29
2025-03-31$4.81M
10-Q · filed 2026-05-15
-$12.58M
derived: sum of 2 quarters · filed 2026-05-15
-$50.33M
10-Q · filed 2026-05-15
-$67.27M
derived: sum of 4 quarters · filed 2026-05-15
2024-12-31-$17.40M
10-Q · filed 2026-02-17
-$55.14M
10-Q · filed 2026-02-17
-$72.08M
derived: sum of 3 quarters · filed 2026-02-17
-$130.01M
derived: sum of 4 quarters · filed 2026-02-17
2024-09-30-$37.74M
10-Q · filed 2025-11-14
-$54.68M
derived: sum of 2 quarters · filed 2025-11-14
-$112.61M
derived: sum of 3 quarters · filed 2025-11-14
-$117.10M
derived: sum of 4 quarters · filed 2025-11-14
2024-06-30-$16.94M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-09-29
-$74.87M
derived: sum of 2 quarters · filed 2025-09-29
-$79.36M
derived: sum of 3 quarters · filed 2025-09-29
-$88.57M
10-K · filed 2025-09-29
-$80.79M
10-K · filed 2024-10-10
2024-03-31-$57.93M
10-Q · filed 2025-05-15
-$15.96M
10-Q · filed 2024-05-15
-$62.42M
derived: sum of 2 quarters · filed 2025-05-15
-$71.63M
10-Q · filed 2025-05-15
-$29.66M
10-Q · filed 2024-05-15
-$94.83M
derived: sum of 4 quarters · filed 2025-05-15
2023-12-31-$4.49M
10-Q · filed 2025-02-19
-$13.70M
10-Q · filed 2025-02-19
-$36.90M
derived: sum of 3 quarters · filed 2025-02-19
-$41.23M
derived: sum of 4 quarters · filed 2025-02-19
2023-09-30-$9.21M
10-Q/A · filed 2025-02-19
-$32.41M
derived: sum of 2 quarters · filed 2025-02-19
-$36.74M
derived: sum of 3 quarters · filed 2025-02-19
-$41.19M
derived: sum of 4 quarters · filed 2025-02-19
2023-06-30-$23.20M
derived: 10-K/A 12 month − 10-Q/A 9 month · filed 2025-02-19
-$27.53M
derived: sum of 2 quarters · filed 2025-02-19
-$31.98M
derived: sum of 3 quarters · filed 2025-02-19
-$39.68M
10-K/A · filed 2025-02-19
2023-03-31-$4.33M
10-Q/A · filed 2025-02-19
-$8.78M
derived: sum of 2 quarters · filed 2025-02-19
-$16.49M
10-Q/A · filed 2025-02-19
-$106.73M
derived: sum of 4 quarters · filed 2025-02-19
2022-12-31-$4.45M
10-Q · filed 2024-02-14
-$12.16M
10-Q · filed 2024-02-14
-$102.40M
derived: sum of 3 quarters · filed 2024-02-14
-$108.61M
derived: sum of 4 quarters · filed 2024-02-14
2022-09-30-$7.71M
10-Q · filed 2023-11-14
-$97.95M
derived: sum of 2 quarters · filed 2023-11-14
-$104.16M
derived: sum of 3 quarters · filed 2023-11-14
-$110.74M
derived: sum of 4 quarters · filed 2023-11-14
2022-06-30-$90.25M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-10-02
-$96.45M
derived: sum of 2 quarters · filed 2023-10-02
-$103.04M
derived: sum of 3 quarters · filed 2023-10-02
-$113.45M
10-K · filed 2023-10-02
2022-03-31-$6.20M
10-Q · filed 2023-05-12
-$12.79M
derived: sum of 2 quarters · filed 2023-05-12
-$23.21M
10-Q · filed 2023-05-12
-$40.57M
derived: sum of 4 quarters · filed 2023-05-12
2021-12-31-$6.59M
10-Q · filed 2023-03-09
-$17.00M
10-Q · filed 2023-03-09
-$34.36M
derived: sum of 3 quarters · filed 2023-03-09
-$38.40M
derived: sum of 4 quarters · filed 2023-03-09
2021-09-30-$10.42M
10-Q · filed 2023-03-07
-$27.78M
derived: sum of 2 quarters · filed 2023-03-07
-$31.82M
derived: sum of 3 quarters · filed 2023-03-07
-$34.74M
derived: sum of 4 quarters · filed 2023-03-07
2021-06-30-$17.36M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27
-$21.40M
derived: sum of 2 quarters · filed 2023-02-27
-$24.32M
derived: sum of 3 quarters · filed 2023-02-27
-$26.69M
10-K · filed 2023-02-27
2021-03-31-$4.04M
10-Q · filed 2022-05-13
-$6.96M
derived: sum of 2 quarters · filed 2022-05-13
-$9.33M
10-Q · filed 2022-05-13
-$13.46M
derived: sum of 4 quarters · filed 2022-05-13
2020-12-31-$2.92M
10-Q · filed 2022-02-14
-$5.29M
10-Q · filed 2022-02-14
-$9.42M
derived: sum of 3 quarters · filed 2022-02-14
-$10.94M
derived: sum of 4 quarters · filed 2022-02-14
2020-09-30-$2.37M
10-Q · filed 2021-11-15
-$6.49M
derived: sum of 2 quarters · filed 2021-11-15
-$8.02M
derived: sum of 3 quarters · filed 2021-11-15
-$9.61M
derived: sum of 4 quarters · filed 2021-11-15
2020-06-30-$4.12M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-09-24
-$5.65M
derived: sum of 2 quarters · filed 2021-09-24
-$7.24M
derived: sum of 3 quarters · filed 2021-09-24
-$11.60M
10-K · filed 2021-09-24
2020-03-31-$1.52M
10-Q · filed 2021-05-17
-$3.11M
derived: sum of 2 quarters · filed 2021-05-17
-$7.48M
10-Q · filed 2021-05-17
-$6.40M
derived: sum of 4 quarters · filed 2021-05-17
2019-12-31-$1.59M
10-Q · filed 2021-02-16
-$5.95M
10-Q · filed 2021-02-16
-$4.88M
derived: sum of 3 quarters · filed 2021-02-16
-$7.75M
derived: sum of 4 quarters · filed 2021-02-16
2019-09-30-$4.36M
10-Q · filed 2020-11-12
-$3.29M
derived: sum of 2 quarters · filed 2020-11-12
-$6.16M
derived: sum of 3 quarters · filed 2020-11-12
-$22.04M
derived: sum of 4 quarters · filed 2020-11-12
2019-06-30$1.07M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-09-23
-$1.80M
derived: sum of 2 quarters · filed 2020-09-23
-$17.68M
derived: sum of 3 quarters · filed 2020-09-23
-$18.12M
10-K · filed 2020-09-23
2019-03-31-$2.87M
10-Q · filed 2020-05-11
-$4.57M
10-Q · filed 2019-05-16
-$18.75M
derived: sum of 2 quarters · filed 2020-05-11
-$19.19M
10-Q · filed 2020-05-11
$35.01M
10-Q · filed 2019-05-16
-$20.77M
derived: sum of 4 quarters · filed 2020-05-11
2018-12-31-$15.88M
10-Q · filed 2020-02-10
-$17.77M
10-Q · filed 2019-02-13
-$16.32M
10-Q · filed 2020-02-10
-$20.16M
10-Q · filed 2019-02-13
-$17.90M
derived: sum of 3 quarters · filed 2020-02-10
-$18.14M
derived: sum of 4 quarters · filed 2020-02-10
2018-09-30-$441.60K
10-Q · filed 2019-11-13
-$2.39M
10-Q · filed 2018-11-14
-$2.02M
derived: sum of 2 quarters · filed 2019-11-13
-$2.25M
derived: sum of 3 quarters · filed 2019-11-13
-$2.38M
derived: sum of 4 quarters · filed 2019-11-13
2018-06-30-$1.58M
derived: 10-K 12 month − 10-Q 9 month · filed 2019-09-30
-$1.81M
derived: sum of 2 quarters · filed 2019-09-30
-$1.94M
derived: sum of 3 quarters · filed 2019-09-30
-$6.46M
10-K · filed 2019-09-30
-$9.30M
10-K · filed 2018-10-01
2018-03-31-$235.96K
10-Q · filed 2019-05-16
-$3.20M
10-Q · filed 2018-05-15
-$365.95K
derived: sum of 2 quarters · filed 2019-05-16
-$4.88M
10-Q · filed 2019-05-16
-$1.29M
derived: sum of 4 quarters · filed 2019-05-16
2017-12-31-$129.99K
10-Q · filed 2019-05-16
-$1.21M
10-Q · filed 2018-02-09
-$1.69M
10-Q · filed 2019-02-13
-$1.05M
derived: sum of 3 quarters · filed 2019-05-16
-$1.41M
derived: sum of 4 quarters · filed 2019-05-16
2017-09-30-$255.18K
10-Q · filed 2019-05-16
-$480.96K
10-Q · filed 2017-11-20
-$922.50K
derived: sum of 2 quarters · filed 2019-05-16
-$1.28M
derived: sum of 3 quarters · filed 2019-05-16
-$1.79M
derived: sum of 4 quarters · filed 2019-05-16
2017-06-30-$667.32K
derived: 10-K 12 month − 10-Q 9 month · filed 2018-10-01
-$1.02M
derived: sum of 2 quarters · filed 2018-10-01
-$1.54M
derived: sum of 3 quarters · filed 2018-10-01
-$2.35M
10-K · filed 2018-10-01
-$2.60M
10-K · filed 2017-09-29
2017-03-31-$353.75K
10-Q · filed 2018-05-15
-$868.14K
derived: sum of 2 quarters · filed 2018-05-15
-$1.69M
10-Q · filed 2017-05-15
-$2.26M
derived: sum of 4 quarters · filed 2018-05-15
2016-12-31-$514.39K
10-Q · filed 2018-02-09
-$1.33M
10-Q · filed 2018-02-09
-$1.91M
derived: sum of 3 quarters · filed 2018-02-09
-$2.41M
derived: sum of 4 quarters · filed 2018-02-09
2016-09-30-$818.77K
10-Q · filed 2017-11-20
-$1.39M
derived: sum of 2 quarters · filed 2017-11-20
-$1.90M
derived: sum of 3 quarters · filed 2017-11-20
-$2.17M
derived: sum of 4 quarters · filed 2017-11-20
2016-06-30-$574.01K
derived: 10-K 12 month − 10-Q 9 month · filed 2017-11-20
-$1.08M
derived: sum of 2 quarters · filed 2017-11-20
-$1.35M
derived: sum of 3 quarters · filed 2017-11-20
-$1.71M
10-K · filed 2017-11-20
2016-03-31-$505.16K
10-Q · filed 2017-05-15
-$780.71K
derived: sum of 2 quarters · filed 2017-05-15
-$1.14M
10-Q · filed 2017-05-15
-$2.74M
derived: sum of 4 quarters · filed 2017-05-15
2015-12-31-$275.54K
10-Q · filed 2017-02-14
-$635.66K
10-Q · filed 2017-02-14
-$2.23M
derived: sum of 3 quarters · filed 2017-02-14
-$3.04M
derived: sum of 4 quarters · filed 2017-02-14
2015-09-30-$360.12K
10-Q · filed 2016-11-14
-$1.95M
derived: sum of 2 quarters · filed 2016-11-14
-$2.77M
derived: sum of 3 quarters · filed 2016-11-14
-$3.64M
derived: sum of 4 quarters · filed 2016-11-14
2015-06-30-$1.59M
derived: 10-K 6 month − 10-Q 3 month · filed 2016-09-28
-$2.41M
10-K · filed 2016-09-28
-$3.28M
derived: sum of 3 quarters · filed 2016-09-28
-$3.60M
derived: sum of 4 quarters · filed 2016-09-28
2015-03-31-$810.77K
10-Q · filed 2016-05-13
-$1.69M
derived: sum of 2 quarters · filed 2016-05-13
-$2.01M
10-Q · filed 2016-05-13
-$2.45M
derived: sum of 4 quarters · filed 2016-05-13
2014-12-31-$877.39K
10-Q · filed 2016-02-12
-$1.20M
10-Q · filed 2016-02-12
-$1.64M
derived: sum of 3 quarters · filed 2016-02-12
-$2.06M
10-K · filed 2016-09-28
2014-09-30-$319.62K
10-Q · filed 2015-11-13
-$757.64K
derived: sum of 2 quarters · filed 2015-11-13
-$1.19M
derived: sum of 3 quarters · filed 2015-11-13
2014-06-30-$438.02K
derived: 10-KT 6 month − 10-Q 3 month · filed 2015-09-28
-$867.43K
10-KT · filed 2015-09-28
2014-03-31-$429.41K
10-Q · filed 2015-05-13
2013-12-31-$2.37M
10-KT · filed 2015-09-28
2013-03-31-$538.12K
10-Q · filed 2014-05-14

Similar stocks

Stock NameCountryMarket CapPE Ratio
PMV Pharmaceuticals, Inc. (PMVP)United States$0.071B-0.95
TENAX THERAPEUTICS, INC. (TENX)United States$0.071B-7.17
PLIANT THERAPEUTICS, INC. (PLRX)United States$0.071B-0.76
Spero Therapeutics, Inc. (SPRO)United States$0.073B17.41
Cingulate Inc. (CING)United States$0.073B-2.64
Yarrow Bioscience, Inc. (YARW)United States$0.070B
Aldeyra Therapeutics, Inc. (ALDX)United States$0.074B-5.57
Connect Biopharma Holdings Ltd (CNTB)$0.069B-2.17
OS Therapies Inc (OSTX)United States$0.076B-2.17
Verrica Pharmaceuticals Inc. (VRCA)United States$0.076B-3.39